These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9375823

  • 1. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
    Jogose JT, Bailey RR, Lynn KL, Robson RA, Wells JE.
    Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K, Irie A, Mashimo S, Endo T, Koshiba K.
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract] [Full Text] [Related]

  • 3. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
    Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D.
    Am J Nephrol; 1999 Jun; 19(6):634-40. PubMed ID: 10592356
    [Abstract] [Full Text] [Related]

  • 4. OKT3 rescue for steroid-resistant rejection in adult liver transplantation.
    Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, Netto G, Goldstein RM, Husberg BS, Klintmalm GB.
    Transplantation; 1993 Jan; 55(1):87-91. PubMed ID: 8420070
    [Abstract] [Full Text] [Related]

  • 5. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K, Tafjord AB, Hartmann A, Eide TC, Holdaas H, Nordal KP, Draganov B, Sødal G, Leivestad T, Fauchald P.
    Transplantation; 1996 Jul 15; 62(1):38-42. PubMed ID: 8693541
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
    Kamath S, Dean D, Peddi VR, Schroeder TJ, Alexander JW, Cavallo T, First MR.
    Transplantation; 1997 Nov 27; 64(10):1428-32. PubMed ID: 9392306
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
    Shennib H, Massard G, Reynaud M, Noirclerc M.
    J Heart Lung Transplant; 1994 Nov 27; 13(3):514-9. PubMed ID: 8061029
    [Abstract] [Full Text] [Related]

  • 8. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S, Emiroglu R, Karakayali F, Yagmurdur MC, Dalgic A, Moray G, Haberal M.
    Transplant Proc; 2005 Sep 27; 37(7):3016-8. PubMed ID: 16213290
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
    Mochon M, Kaiser B, Palmer JA, Polinsky M, Flynn JT, Caputo GC, Baluarte HJ.
    Pediatr Nephrol; 1993 Jun 27; 7(3):259-62. PubMed ID: 8518094
    [Abstract] [Full Text] [Related]

  • 10. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ, Elkhammas EA, Henry ML, Ferguson RM.
    Transplantation; 1993 May 27; 55(5):1023-9. PubMed ID: 8497875
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
    Yu LX.
    Zhonghua Wai Ke Za Zhi; 1993 Dec 27; 31(12):754-5. PubMed ID: 8033708
    [Abstract] [Full Text] [Related]

  • 15. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
    Wagner FM, Reichenspurner H, Uberfuhr P, Kur F, Kaulbach HG, Meiser BM, Ziegler U, Reichart B.
    J Heart Lung Transplant; 1994 Dec 27; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
    [Abstract] [Full Text] [Related]

  • 16. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection.
    Patschan D, Kribben A, Pietruck F, Lutz J, Binek M, Philipp T, Heemann U, Witzke O.
    Nephron Clin Pract; 2006 Dec 27; 103(3):c94-9. PubMed ID: 16534238
    [Abstract] [Full Text] [Related]

  • 17. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF.
    Transplant Proc; 1993 Apr 27; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract] [Full Text] [Related]

  • 18. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R, Peace D, Jollife LK, Haverty T, Bluestone JA, Thistlethwaite JR.
    Transplantation; 1999 Sep 15; 68(5):608-16. PubMed ID: 10507477
    [Abstract] [Full Text] [Related]

  • 19. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F.
    Transpl Int; 1998 Sep 15; 11(3):231-6. PubMed ID: 9638854
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of the use of OKT3 to treat steroid-resistant acute renal allograft rejection.
    Rowe PA, Fan KS, Gardiner DS, Macpherson SG, Bradley JA, Rodger RS, Junor BJ, Briggs JD.
    Transpl Int; 1994 Jul 15; 7(4):278-83. PubMed ID: 7916928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.